NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis $1.47 +0.10 (+7.30%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$1.46 -0.01 (-1.02%) As of 04/23/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Humacyte Stock (NASDAQ:HUMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Humacyte alerts:Sign Up Key Stats Today's Range$1.40▼$1.5450-Day Range$1.15▼$3.9152-Week Range$1.15▼$9.97Volume3.21 million shsAverage Volume3.58 million shsMarket Capitalization$228.02 millionP/E RatioN/ADividend YieldN/APrice Target$13.71Consensus RatingBuy Company OverviewHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More… Humacyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreHUMA MarketRank™: Humacyte scored higher than 49% of companies evaluated by MarketBeat, and ranked 484th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHumacyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHumacyte has only been the subject of 3 research reports in the past 90 days.Read more about Humacyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($1.27) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 11.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Humacyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.57% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Humacyte has recently increased by 2.03%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted21.57% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Humacyte has recently increased by 2.03%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.90 News SentimentHumacyte has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Humacyte this week, compared to 10 articles on an average week.Search InterestOnly 17 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows21 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $118,224.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.20% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Humacyte's insider trading history. Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Stock News HeadlinesShamik J. Parikh Acquires 7,500 Shares of Humacyte, Inc. (NASDAQ:HUMA) StockApril 15, 2025 | insidertrades.comInsider Buying: Humacyte, Inc. (NASDAQ:HUMA) Director Acquires 50,000 Shares of StockApril 9, 2025 | insidertrades.comThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warning signs are everywhere. Economist Addison Wiggin reveals what’s coming.April 24, 2025 | Banyan Hill Publishing (Ad)Contrasting Genetic Technologies (NASDAQ:GENE) and Humacyte (NASDAQ:HUMA)April 19, 2025 | americanbankingnews.comHumacyte Challenges FDA Petition Amidst ControversyApril 18, 2025 | tipranks.comHumacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should KnowApril 3, 2025 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comHumacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma TreatmentMarch 31, 2025 | markets.businessinsider.comSee More Headlines HUMA Stock Analysis - Frequently Asked Questions How have HUMA shares performed this year? Humacyte's stock was trading at $5.05 at the beginning of the year. Since then, HUMA shares have decreased by 70.9% and is now trading at $1.47. View the best growth stocks for 2025 here. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) posted its earnings results on Friday, March, 28th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.07. The business had revenue of $7.23 million for the quarter, compared to analysts' expectations of $0.64 million. Read the conference call transcript. Who are Humacyte's major shareholders? Humacyte's top institutional shareholders include Wealth Effects LLC (0.06%), Hamilton Lane Advisors LLC (0.02%) and Columbia Advisory Partners LLC (0.01%). Insiders that own company stock include Brady W Dougan, Laura E Niklason, Gordon M Binder, Kathleen Sebelius, Dale A Sander, William John Scheessele, Michael T Constantino, Shamik J Parikh and Heather Ledbetter Prichard. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Humacyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Humacyte investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings3/28/2025Today4/24/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HUMA CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$13.71 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+832.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-942.81% Return on Assets-93.82% Debt Debt-to-Equity RatioN/A Current Ratio1.10 Quick Ratio1.10 Sales & Book Value Annual Sales$1.57 million Price / Sales145.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book11.31Miscellaneous Outstanding Shares155,119,000Free Float111,763,000Market Cap$228.02 million OptionableOptionable Beta1.62 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:HUMA) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.